Navigation Links
Haemonetics Reports Third Quarter of Fiscal 11
Date:1/31/2011

715Transformation and deal costs

9,345-Global Med employment contracts

2,122-11,467-Free cash flow before transformation and deal costs

$69,294$49,715Haemonetics Corporation Financial SummaryReconciliation of Non-GAAP MeasuresHaemonetics has presented supplemental non-GAAP financial measures as part of this earnings release.  A reconciliation is provided below that reconciles each non-GAAP financial measure with the most comparable GAAP measure.  The presentation of non-GAAP financial measures should not be considered in isolation from, or as a substitute for, the most directly comparable GAAP measures.  There are material limitations to the usefulness of non-GAAP measures on a standalone basis, including the lack of comparability to the GAAP financial results of other companies.These measures are used by management to monitor the financial performance of the business, inform business decision making, and forecast future results.  Performance targets for management are established based upon these non-GAAP measures.  In the reconciliations below, we have removed restructuring and deal integration costs from our GAAP expenses.  Our restructuring is related to the integration of Global Med Technologies and the repositioning of our sales force.  We believe this information is useful for investors because it allows for an evaluation of the Company with a focus on the performance of our core operations.Non-GAAP Gross Profit
The use of these non-GAAP measures allows management to monitor the level of total gross profits without the costs of our business transformation.  We establish our budgets, forecasts, and performance targets on this basis.Non-GAAP S,G&A and Non-GAAP Operating Expenses
The use of this non-GAAP measure allows management to monitor the ongoing level of spend that is necessary to support the business in a period when we are not transforming our business or completing an acquis
'/>"/>

SOURCE Haemonetics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Haemonetics Receives Favorable Ruling in Patent Lawsuit against Competitive Technology
2. Neogen Reports 33% Increase in Net Income
3. Cardium Reports Excellagen Matrix Clinical Study Results Accepted for Publication by Peer-Reviewed Journal, and Updates Product Plans
4. New Topical Patent Research Reports Recently Published at MarketPublishers.com
5. YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387
6. Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors
7. GeneLink Reports Third Quarter Results
8. Imagenetix, Inc. Reports Second Quarter 2011 Results
9. Transgenomic Reports Third Quarter Financial Results
10. Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results
11. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2011 Results; Teleconference and Webcast to be held on November 16, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 Terascala, the industry leader ... Alan Swahn, a former vice president of product management ... vice president of marketing. Terascala’s software when combined with ... create the highest performance and most reliable solutions for ... guide Terascala’s channel expansion and broaden its product portfolio. ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 OMICS ... Bioanalytical techniques during 18-20 August, 2014 at Double Tree ... review the recent developments in Analytical & Bioanalytical research ... globe. , Speaking on this occasion, Dr. Srinubabu Gedela, ... Analytica Acta conference is a remarkable one in bringing ...
(Date:7/10/2014)... CROWN POINT, Ind. , July 10, ... recently expanded its use of capnography for ... a growing group of healthcare leaders in ... Capnography measures how effectively patients are breathing ... respiratory depression occurs. By measuring the amount ...
(Date:7/10/2014)... 2014 /PRNewswire-iReach/ -- Tute Genomics, the leader ... an agreement with Lineagen, Inc., to provide ... Dx PLUS.  Lineagen, focused on the ... currently offers FirstStep Dx PLUS, a ... by healthcare providers as a first-line genetic ...
Breaking Biology Technology:Terascala Expands Executive Team 2Terascala Expands Executive Team 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4
... BONITA SPRINGS, Fla., March 4 Tigris Pharmaceuticals, ... announced that its Investigational New Drug (IND) application ... accepted by the U.S. Food and Drug Administration. ... Phase I study evaluating the safety of GGTI-2418 ...
... from Collaboration Applying forensicgem(TM) Technology to CBI,s ... of Forensic Sciences Annual Meeting -- Shows ... Yield, Simplify Workflow and Minimize Potential for ... New Zealand, and RICHMOND, Va., March 4 ...
... 2008 Key milestones, - Strong R&D investments, especially in EHT Dx21 ... - Recruitment of 311 samples achieved for EHT Dx21, ... - Expansion of the strategic collaboration with Allergan and extension, ... - Appointment of a new Management Board, - New positioning of ...
Cached Biology Technology:FDA Accepts Investigational New Drug (IND) Application for Tigris Pharmaceutical's GGTI-2418 2Commonwealth Biotechnologies Presents Data at Forensic Sciences Meeting Confirming Benefits of ZyGEM's DNA Extraction Technology 2Commonwealth Biotechnologies Presents Data at Forensic Sciences Meeting Confirming Benefits of ZyGEM's DNA Extraction Technology 3ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 2ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 3ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 4ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 5ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 6ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 7ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 8ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 9ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 10ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 11
(Date:7/11/2014)... that let nerve cells send out electrical signals, Johns ... tactic that may offer a new way to protect ... responsible way. , Their findingthat naturally occurring insect ... for a closely related onesuggests that insecticides can be ... like bees. A summary of the research, led by ...
(Date:7/10/2014)... , June 30, 2014  Aware, Inc. (NASDAQ: ... and services, previously announced on June 26, 2014 that ... dividend of $1.75 per share, or approximately $40 million ... July 10, 2014 and a payment date of July ... that it had set an ex-dividend date for this ...
(Date:7/10/2014)... , July 3, 2014 According ... by Type (Swipe And Area), Material (Optical Prism, Pizeoelectric, ... Commercial Security and Banking & Finance), and Geography - ... by MarketsandMarkets, the global Fingerprint Sensors Market is projected ... high CAGR of 16.8% from 2014 to 2020. ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3
... at the National Institute of Standards and Technology (NIST) ... refrigerant fluids with low "global warming potential" (GWP) ... many decades as well as other desirable performance ... most extensive systematic search for a new class of ...
... /PRNewswire-iReach/ -- Global Information Inc is pleased to offer ... conferences around the world. Early Bird registration prices end ... save up to 15%. (Photo: http://photos.prnewswire.com/prnh/20120918/CG76491 ... 11, 2013 | San Francisco, California CHI,s ...
... pioneering wildlife ecologist Aldo Leopold was a meticulous taker of ... bench at his Sauk County shack in Depression-era Wisconsin, Leopold ... with the first pre-dawn calls of the indigo bunting or ... songs he heard, when he heard them, and details such ...
Cached Biology News:New NIST screening method identifies 1,200 candidate refrigerants to combat global warming 2International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering 2International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering 3International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering 4Aldo Leopold's field notes score a lost 'soundscape' 2Aldo Leopold's field notes score a lost 'soundscape' 3
... Well Plate Sterile with ... range of 384-well plates ... screening and research. These ... and are suitable for ...
Request Info...
... to Cytokeratin 5 / 6 Cytokeratin ... weight, basic type of cytokeratin expressed in ... layers of stratified epithelia as well as ... cells and mesothelioma. Cytokeratin 6 (56 kD) ...
Bovine Coronary Artery Endothelial Cells (BCAEC) (>500,000 cells)...
Biology Products: